• LAST PRICE
    3.4100
  • TODAY'S CHANGE (%)
    Trending Up0.2100 (6.5625%)
  • Bid / Lots
    3.2100/ 1
  • Ask / Lots
    3.4000/ 3
  • Open / Previous Close
    3.2200 / 3.2000
  • Day Range
    Low 3.1900
    High 3.4100
  • 52 Week Range
    Low 2.5300
    High 11.1100
  • Volume
    79,539
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Mar 27, 2024

  • Mar 26, 2024

      Show headlines and story abstract
    • 11:53AM ET on Tuesday Mar 26, 2024 by MT Newswires
      Companies Mentioned: VIGL
      11:53 AM EDT, 03/26/2024 (MT Newswires) -- Vigil Neuroscience (VIGL) has an average rating of outperform and price targets ranging from $4 to $24, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic resear...
    • 7:05AM ET on Tuesday Mar 26, 2024 by GlobeNewswire
      Companies Mentioned: VIGL
    • 7:05AM ET on Tuesday Mar 26, 2024 by Dow Jones
      Companies Mentioned: VIGL
    • 7:05AM ET on Tuesday Mar 26, 2024 by Dow Jones
      Companies Mentioned: VIGL

      This press release includes certain disclosures that contain "forward-looking statements" of Vigil Neuroscience ("Vigil" or the "Company") that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, express or implied statements regarding: the Company's strategy, business plans and focus; the progress and timing of the clinical development of Vigil's programs, including the availability of, and expected timing for reporting, data from both the IGNITE Phase 2 clinical trial and the VG-3927 Phase 1 clinical trial; beliefs about observations made analyzing preclinical study and clinical trial data to date; the anticipated impact of the VG-3927 partial clinical hold on the Company's clinical development plans and beliefs about the maximum exposure limit, regulatory progress and clinical progress for VG-3927; the success and timing of the Company's interactions with regulatory authorities; and the expectation that the Company's cash runway will be sufficient into the second half of 2025. Forward-looking statements are based on Vigil's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; the timing and content of additional regulatory information from the FDA; the Company's ability to work with the FDA to successfully remove the partial clinical hold on VG-3927; whether Vigil's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (SEC), including Vigil's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, its upcoming Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent filings Vigil makes with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Vigil undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information on this page as current or accurate after its publication date.

Peers Headlines